BusinessCidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVCBy Nasdaq OMXFeb 21, 2017, 12:30 PM UTC
BusinessCidara Therapeutics Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriter’s Option to Purchase Additional SharesBy Nasdaq OMXOct 13, 2016, 1:20 PM UTC
BusinessCidara Therapeutics Announces Commencement of Public Offering of Common StockBy Nasdaq OMXOct 6, 2016, 8:02 PM UTC
BusinessCidara Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-OncologyBy Nasdaq OMXSep 20, 2016, 8:05 PM UTC
BusinessCidara Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate UpdateBy Nasdaq OMXMar 18, 2016, 11:30 AM UTC
